Properties (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Gilead_Sciences
acquired_by_Gilead_Sciences |
| gptkbp:advertising |
focus on niche markets
|
| gptkbp:businessModel |
biopharmaceutical development
|
| gptkbp:clinicalTrials |
Phase 3
various cancer treatments ongoing clinical studies advanced drug development processes late-stage clinical trials multiple sites globally positive results in trials |
| gptkbp:collaborations |
gptkb:National_Cancer_Institute
academic institutions collaborative research efforts collaborative research initiatives |
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:community_service |
patient support programs
|
| gptkbp:dataUsage |
positive efficacy data
|
| gptkbp:drugInterdiction |
rigorous approval process
targeted delivery systems |
| gptkbp:employees |
approximately 300
|
| gptkbp:enrollment |
diverse patient demographics
|
| gptkbp:feedback |
improved patient outcomes
focus on improving patient outcomes |
| gptkbp:financialPerformance |
strong financial growth
|
| gptkbp:focus |
oncology
|
| gptkbp:founded |
1982
|
| gptkbp:founder |
gptkb:Dr._David_M._Goldenberg
|
| gptkbp:funding |
secured research funding
|
| gptkbp:headquarters |
gptkb:Morris_Plains,_New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunomedics
|
| gptkbp:industry |
active in the biotech industry
|
| gptkbp:innovation |
commitment to innovation
|
| gptkbp:investmentFocus |
various venture capital firms
significant investments in R&D |
| gptkbp:leadership |
gptkb:Dr._Behzad_Aghazadeh
|
| gptkbp:leads |
gptkb:Dr._David_M._Goldenberg
|
| gptkbp:market |
$21 billion (2020)
|
| gptkbp:notableEvent |
Trodelvy
|
| gptkbp:partnerships |
various pharmaceutical companies
biotech collaborations |
| gptkbp:patentCitation |
multiple patents in oncology
|
| gptkbp:patentType |
2020
|
| gptkbp:publications |
numerous publications in journals
|
| gptkbp:reach |
international presence
|
| gptkbp:regulatoryCompliance |
various international approvals
|
| gptkbp:research |
Dr. Michael A. McGowan
|
| gptkbp:research_areas |
breast cancer
immunotherapy non-small cell lung cancer innovative therapeutic approaches new therapeutic innovations urothelial cancer |
| gptkbp:research_focus |
antibody-drug conjugates
|
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:safety_features |
favorable safety profile
|
| gptkbp:specialties |
experienced clinical team
expertise in antibody therapies expertise in clinical trials |
| gptkbp:stockExchange |
IMMU
|
| gptkbp:tributaryOf |
multiple drug candidates
|
| gptkbp:website |
www.immunomedics.com
|